We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
Doximity (DOCS - Free Report) ended the recent trading session at $40.88, demonstrating a +0.62% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The medical social networking site's shares have seen an increase of 12.05% over the last month, surpassing the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. The company's upcoming EPS is projected at $0.26, signifying a 18.18% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $127.05 million, indicating a 11.83% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $1.05 per share and revenue of $520.23 million, which would represent changes of +10.53% and +9.43%, respectively, from the prior year.
Any recent changes to analyst estimates for Doximity should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Doximity possesses a Zacks Rank of #3 (Hold).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 38.57. This expresses a premium compared to the average Forward P/E of 20.94 of its industry.
It's also important to note that DOCS currently trades at a PEG ratio of 4.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. DOCS's industry had an average PEG ratio of 1.86 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 162, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
Doximity (DOCS - Free Report) ended the recent trading session at $40.88, demonstrating a +0.62% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The medical social networking site's shares have seen an increase of 12.05% over the last month, surpassing the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. The company's upcoming EPS is projected at $0.26, signifying a 18.18% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $127.05 million, indicating a 11.83% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $1.05 per share and revenue of $520.23 million, which would represent changes of +10.53% and +9.43%, respectively, from the prior year.
Any recent changes to analyst estimates for Doximity should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Doximity possesses a Zacks Rank of #3 (Hold).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 38.57. This expresses a premium compared to the average Forward P/E of 20.94 of its industry.
It's also important to note that DOCS currently trades at a PEG ratio of 4.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. DOCS's industry had an average PEG ratio of 1.86 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 162, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.